• Fab arms are responsible for antigen binding and have been extensively engineered for developing highly specific and synthetic antibodies against numerous targets ( 4 ). (frontiersin.org)
  • Impressively, antibody fragments such as bispecific T-cell engager, bispecific killer cell engager, trispecific killer cell engager, tandem diabody, and dual-affinity-retargeting are showing exciting results in terms of recruiting and activating self-immune effector cells to target and lyse tumor cells. (frontiersin.org)
  • Each individual therapy is associated with its own specific side effects, as different bispecific antibodies target particular cells and trigger distinct immune responses. (immuno-oncologynews.com)